# 2026-12612: FTC Seeks Comment on Drug Company Settlement Deal

2026-12612, Aurobindo and Lannett; Analysis of Proposed Agreement Containing Consent Orders To Aid Public Comment, is a Federal Register notice from Federal Trade Commission published 2026-06-23, effective Comments must be received on or before July 23, 2026.; PRIA reads it as touching household money (as of 2026-06-30).

- Canonical: https://policyrisk.com/federal-register/2026-12612
- As of: 2026-06-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12612
- Title: Aurobindo and Lannett; Analysis of Proposed Agreement Containing Consent Orders To Aid Public Comment
- Type: Notice
- Agencies: Federal Trade Commission
- Citation: 91 FR 37403
- Published: 2026-06-23
- Effective: Comments must be received on or before July 23, 2026.
- Comments close: 2026-07-23
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-30

## In one line

FTC Seeks Comment on Drug Company Settlement Deal

## Summary

The Federal Trade Commission is asking for your thoughts on a deal with Aurobindo and Lannett, two drug companies accused of unfair competition. The companies agree to stop certain practices that hurt competition, helping keep medicine prices fair. You have until July 23, 2026, to share your opinion before the deal is final.

## Abstract

The consent agreement in this matter settles alleged violations of Federal law prohibiting unfair methods of competition. The attached Analysis of Proposed Agreement Containing Consent Orders to Aid Public Comment describes both the allegations in the complaint and the terms of the consent order--embodied in the consent agreement--that would settle these allegations.

## Effects PRIA read

- Divestiture to Restore Drug Competition: benefit, medium. The FTC says Aurobindo's proposed $250 million acquisition of Lannett could raise prices for four generic medicines, so the companies must sell all rights and assets for those products to Quagen Pharmaceuticals Inc. The four products are mycophenolate mofetil oral suspension, niacin extended releas…

## Related documents

- [2026-20143](https://policyrisk.com/federal-register/2026-20143): Rule on Impersonation of Government and Businesses, 2026-10-01
- [2026-20078](https://policyrisk.com/federal-register/2026-20078): Petition for Rulemaking of Malik Tony Singleton, 2026-09-30
- [2026-19598](https://policyrisk.com/federal-register/2026-19598): Rules of Practice, 2026-09-24
- [2026-19597](https://policyrisk.com/federal-register/2026-19597): Rules of Practice, 2026-09-24
- [2026-19289](https://policyrisk.com/federal-register/2026-19289): FleetCor Technologies; Analysis of Proposed Consent Order To Aid Public Comment, 2026-09-22
- [2026-18853](https://policyrisk.com/federal-register/2026-18853): Civil Penalty Inflation Adjustments, 2026-09-15

## Sources
- [2026-12612 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/23/2026-12612/aurobindo-and-lannett-analysis-of-proposed-agreement-containing-consent-orders-to-aid-public-comment)
- [2026-12612 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-23/pdf/2026-12612.pdf)

## Related
- [Previous: 2026-12611, Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public…](https://policyrisk.com/federal-register/2026-12611)
- [Next: 2026-12613, Order Granting Conditional Exemptive Relief, Pursuant to Sections 17A and 36(a)…](https://policyrisk.com/federal-register/2026-12613)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12612 (as of 2026-06-30).